SCHEMBL1925482

SCHEMBL1925482

NC(=O)c1[nH]cc(CCC(=O)O)c1-c1ccc(NC(=O)Nc2ccc(OC(F)F)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 1/20 0.44
MAPT P10636 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 1/20 0.36
IDO1 P14902 1/20 0.36
PPARA Q07869 1/20 0.35
POLB P06746 2/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
ATM Q13315 1/20 0.34
PDGFRB P09619 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926602 0.87 KDM4E (0.46) MAPTMEN1KMT2ASMN1; SMN2POLB
SCHEMBL1923925 0.86 MAPT (0.50) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924602 0.86 EPHX2 (0.49) STING1MAPTMEN1KMT2AHTT
SCHEMBL1924464 0.86 ALDH1A1 (0.38) STING1MAPTMEN1KMT2AHTT
SCHEMBL1923912 0.83 KDR (0.48) STING1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1925334 0.83 EPHX2 (0.48) STING1MAPTMEN1KMT2AKDR
SCHEMBL1925481 0.83 STING1 (0.47) STING1MAPTMEN1KMT2ALMNA
SCHEMBL1926895 0.82 MAPT (0.41) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924884 0.81 MEN1 (0.42) MAPTMEN1KMT2ASMN1; SMN2POLB
SCHEMBL1925337 0.80 PKM (0.47) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed